Recent Advances in HIV-1 Gag Inhibitor Design and Development
Open accessThe DOI matches its Crossref record; 150 of the 153 references it cites were found in a registry or an index.
Abstract
Acquired Immune Deficiency Syndrome (AIDS) treatment with combination antiretroviral therapy (cART) has improved the life quality of many patients since its implementation. However, resistance mutations and the accumulation of severe side effects associated with cART remain enormous challenges that need to be addressed with the continual design and redesign of anti-HIV drugs. In this review, we focus on the importance of the HIV-1 Gag polyprotein as the master coordinator of HIV-1 assembly and maturation and as an emerging drug target. Due to its multiple roles in the HIV-1 life cycle, the individual Gag domains are attractive but also challenging targets for inhibitor design. However, recent encouraging developments in targeting the Gag domains such as the capsid protein with highly potent and potentially long-acting inhibitors, as well as the exploration and successful targeting of challenging HIV-1 proteins such as the matrix protein, have demonstrated the therapeutic viability of this important protein. Such Gag-directed inhibitors have great potential for combating the AIDS pandemic and to be useful tools to dissect HIV-1 biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Surface conservation of the HIV-1 Gag polyprotein and inhibitor target sites. Alignment of 9547 HIV-1 Gag sequences were retrieved from the HIV Los Alamos database (www.hiv.lanl.gov). Sequences were aligned against the HxBc2 reference. Conservation analysis was performed using the ConSurf server [10]. Structures of the HIV-1 Gag domains with PDB entries: matrix, 2H3Z; capsid, 6ES8; sp2, 1U57; nucleocapsid, 2M3Z; p6, 2C55. Orange boxes represent target sites for inhibitor binding highlighted in this review. Low conservation in light cyan to high conservation in dark purple.Gag’s constituent proteins act at different points in the viral life cycle. MA binds specifically to phosphoinositide 4,5-bisphosphate (PI [4,5]P2) and specific phospholipids on the plasma membrane, triggering the exposure of an attached myristoyl (myr) chain and directing Gag to the membrane. This membrane interaction is required for the correct incorporation of the viral envelope protein (Env) into the budding virus [11,12,13,14]. In the late stages of the replication cycle, CA is responsible for the assembly of Gag at the plasma membrane by providing intermolecular contact sites for Gag oligomerization at the plasma membrane [15,16]. In the early stages of replication, CA disassembly regulates the process of reverse transcription, and its engagement of cellular transportins and nuclear pore components facilitate the import of the viral pre-integration complex into the nucleus, where integration takes place [17]. NC functions as a nucleic acid chaperone at multiple steps in the HIV-1 replication cycle, and it’s overall positively charged character and two zinc-finger motifs allow it to interact with viral genomic RNA via the RNA packaging signal and thereby facilitate virion assembly [18,19,20,21]. Finally, the p6 domain (late domain) recruits the endosomal sorting complex required for transport (ESCRT) machinery to promote virus budding and final release [22]. Two spacer peptides (SP1 and SP2) flanking the NC domain regulate the kinetics of Gag maturation, and SP1 also provides, as part of the C-terminus of CA, another Gag-Gag multimerization interface [23,24]. Because Gag functions in so many different aspects of viral infection and replication, Gag inhibitors have the potential to exert their effects in both early and late stages of the replication cycle, making this polyprotein a particularly attractive target for the development of new therapeutics.](https://figures.cochat.ai/paper-figures/fa72841e53e64979b7a5c91ac99c660f/recent-advances-in-hiv-1-gag-inhibitor-design-and-development-figure-2.jpg)

![Figure 4 MA inhibitors targeting the PI[4,5]P2 binding site. (A) The NMR structure of MA with its myristic acid (in yellow) buried in a hydrophobic groove at the N-terminus (PDB code: 2H3I). (B) The NMR structure of MA bound to di-C4-PI[4,5]P2 displacing the myristic acid (PDB code: 2H3Z). (C) Docking model of compound 7 bound to MA and displacing di-C4-PI[4,5]P2. In red are the residues highlighted that are involved in di-C4-PI[4,5]P2 binding.](https://figures.cochat.ai/paper-figures/08e949ba452943f1a7098f286d16c3e7/recent-advances-in-hiv-1-gag-inhibitor-design-and-development-figure-4.jpg)







![Figure 12 Zinc ejecting mechanisms: Class 1) Electrophilic attack of the zinc fingers. The nucleophilic attack of the cysteine 39 results in the formation of a thioester by SAMTs. This covalent linkage stimulates the reaction of additional reactants with the other Cys residues of the same motif and leads to reduction in Zn2+ affinity of the zinc finger and finally zinc ejection and NC unfolding [131]. Class 2) Zinc chelation by the two carbonyl oxygens of the ester from NVO38 [133]. Class 3) Covalent binding of Cys residues by platinum (Pt) as represented by trans-chlorobispyridine(9-ethylguanine)platinum(II) [137]. Cys (N) and Cys (C) represent N-terminal and C-terminal cysteines in the zinc finger.](https://figures.cochat.ai/paper-figures/6e7a2b9588af4184aa04e818cc6866d6/recent-advances-in-hiv-1-gag-inhibitor-design-and-development-figure-12.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys
Stremlau, M., Owens, C. M., Perron, M. J., Kiessling, M., Autissier, P., & Sodroski, J. (2004) · Nature · doi:10.1038/nature02343 · Cited by 1,816
Origins of HIV and the AIDS Pandemic
Sharp, P. M., & Hahn, B. H. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006841 · Cited by 1,496
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369
Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir627 · Cited by 1,331 · cited 1×
“Long-term cART therapy also leads to side effects and age-related comorbidities such as diabetes, cardiovascular, renal, and bone diseases and can result in a reduced life expectancy of HIV-1 infected patients [7,8].”
BackgroundCyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other Retroviruses
Gao, D., Wu, J., Wu, Y.-T., Du, F., Aroh, C., Yan, N., Sun, L., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1240933 · Cited by 992
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
HIV-1 assembly, budding, and maturation
Sundquist, W. I., & Krausslich, H.-G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006924 · Cited by 814
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B
Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V., & Goff, S. P. (1993) · Cell · doi:10.1016/0092-8674(93)90637-6 · Cited by 802
Martin-Serrano, J., Zang, T., & Bieniasz, P. D. (2001) · Nature Medicine · doi:10.1038/nm1201-1313 · Cited by 710
Research works printed but not linked: 2
- Tse, W.C., Link, J.O., Mulato, A., Niedziela-Majka, A., Rowe, W., Somoza, J.R., Villasenor, A.G., Yant, S.R., Zhang, J.R., and Zheng, J. (2017, January 13–16). Discovery of Novel Potent HIV Capsid Inhibitors with Long-acting Potential. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA.
- Yant, S.R., Mulato, A., Stepan, G., Villasenor, A.G., Jin, D., and Margot, N.A. (2019, January 4–7). GS-6207, a potent and selective first-in-class long-acting HIV-1 capsid inhibitor. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA.
Cited by
Sever, B., Otsuka, M., Fujita, M., & Ciftci, H. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073659 · Cited by 77
Jiang, X., Wu, G., Zalloum, W. A., Meuser, M. E., Dick, A., Sun, L., Chen, C., Kang, D., Jing, L., Jia, R., et al. (2019) · RSC Advances · doi:10.1039/c9ra05869a · Cited by 61
Self-citationZhuang, S., & Torbett, B. E. (2021) · Viruses · doi:10.3390/v13030417 · Cited by 55
The Interplay between HIV-1 Gag Binding to the Plasma Membrane and Env Incorporation
Murphy, R. E., & Saad, J. S. (2020) · Viruses · doi:10.3390/v12050548 · Cited by 30
Xu, S., Sun, L., Dick, A., Zalloum, W. A., Huang, T., Meuser, M. E., Zhang, X., Tao, Y., Cherukupalli, S., Ding, D., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113903 · Cited by 28
Self-citation
Metadata
- Authors
- Dick, A., & Cocklin, S.
- Affiliations
- Drexel University (US)
- Corresponding author
- Cocklin, Simon
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-04-07
- Volume
- 25
- Issue
- 7
- Pages
- 1687
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7181048
- OpenAlex
- W3015551811
- Cited by
- 28
- References
- 153
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 8 · 2020: 1
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (NS089435, GM125396)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- HIV-1 Gag polyprotein, capsid protein, matrix protein, antiretroviral drug design, drug resistance, HIV-1 life cycle
- MeSH terms
- Acquired Immunodeficiency Syndrome, Humans, HIV-1, HIV Protease Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, Capsid Proteins, gag Gene Products, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in HIV-1 Gag Inhibitor Design and Development. https://app.cochat.ai/papers/10.3390/molecules25071687
- The paper
- Dick, A., & Cocklin, S. (2020). Recent Advances in HIV-1 Gag Inhibitor Design and Development. Molecules. https://doi.org/10.3390/molecules25071687
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.